Bioluminescence Imaging Allows Monitoring Hepatitis C Virus Core Protein Inhibitors in Mice by Du, Juan et al.
Bioluminescence Imaging Allows Monitoring Hepatitis C














1Beijing Institute of Transfusion Medicine, Beijing, China, 2Ningxia Medical University, Yinchuan, China
Abstract
Background: The development of small molecule inhibitors of hepatitis C virus (HCV) core protein as antiviral agents has
been intensively pursued as a viable strategy to eradicate HCV infection. However, lack of a robust and convenient small
animal model has hampered the assessment of in vivo efficacy of any antiviral compound.
Methodology/Principal Findings: The objective of this work was to develop a novel method to screen anti-core protein
siRNA in the mouse liver by bioluminescence imaging. The inhibitory effect of two shRNAs targeting the highly conserved
core region of the HCV genome, shRNA452 and shRNA523, was examined using this method. In the transient mouse model,
the effect of shRNA-523 was detectable at as early as 24 h and became even more pronounced at later time points. The
effect of shRNA-452 was not detectable until 48 h post-transduction. In a stable mouse model, shRNA523 reduced luciferase
levels by up to 76.4626.0% and 91.868.0% at 6 h and 12 h after injection respectively, and the inhibitory effect persisted
for 1 day after a single injection while shRNA-Scramble did not seem to have an effect on the luciferase activity in vivo.
Conclusions/Significance: Thus, we developed a simple and quantitative assay for real-time monitoring of HCV core protein
inhibitors in mice.
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Introduction
HCV infection is a major cause of chronic liver diseases, which
often progresses to liver cirrhosis and hepatocellular carcinoma (up
to 20%) [1]. No vaccine is currently available, and current treatment
options involving interferon-a (IFN-a) alone or in combination with
ribavirin are ineffective with substantial side effects. Therefore, safer
and more efficient therapeutic agents are needed.
HCV is an enveloped RNA virus that belongs to the family
Flaviviridae [2].HCV has a single stranded, positive polarity RNA
encoding for a polyprotein precursor of about 3000 amino acids,
which is further cleaved into 10 mature proteins. The HCV core
protein that forms the nucleocapsid is the most conserved protein
among the six major HCV genotypes [3,4]. An immature core
protein (p23, residues 1–191) is cleaved by host signal peptide
peptidase (SPPase) to generate the mature core protein (p21)
within the signal sequence, which is estimated to be between 173
to 181 amino acids in length [5–7].The mature core protein plays
vital roles in modulating gene transcription, cell proliferation, cell
death, oxidative stress, and immunomodulation in host cells [8–
12]. Small molecule inhibitors of HCV core protein as antiviral
agents have been under intensive development as a viable strategy
to eradicate HCV infection, yet lack of a robust and convenient
small animal model has hindered the assessment of in vivo efficacy
of any antiviral compounds.
In the present work, we established a transient mouse model and
stable mouse model by hydrodynamics methods to screen of HCV
core protein inhibitors. The inhibitory effect of hairpin shRNAs
targeting the core region of the HCV genome was monitored in the
mouse liver by bioluminescence imaging. Finally, we found that the
expression level of core protein could be reflected by the activity of Fluc
in the mouse model, and shRNA targeting HCV core protein could
effectively downregulate core gene and Fluc gene expression in vivo.
These models could be used for screening anti-HCV compounds.
Materials and Methods
Mice
C57BL/6 mice (male, 4–6 weeks) were obtained from and fed in
National Beijing Center for Drug Safety Evaluation and Research
(NBCDSER).This study was approved by the ethics committee of
the NBCDSER (Permit No.09-1425).
Plasmids construction
pCMVInt and pT-attB, as were previously described [13], were
kindly provided by M. P. Calos, Department of Genetics, Stanford
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14043University, USA. Plasmid pGL3-attB-Fluc (Fig. 1A) was generat-
ed by cloning a 297-bp fragment from pT-attB containing the
minimal length FC31 attB site and surrounding sequence into the
Kpn I site of pGL3-EI-EII-Pc [14]. For the generation of pGL3-
attB-CoreFluc, HCV core sequence was amplified by PCR using
clone Con1 as the template and was cloned into the Nco I site
upstream of the firefly luciferase gene of pGL3-attB-Fluc.In pGL3-
attB-CoreFluc, the firefly luciferase (FLuc) gene was fused in-frame
to the downstream of HCV core gene by a short linker gene
(GGTGGTGGTTCCGGTGGTGGT). Plasmid pGL3-attB-Core
was generated by deleting the Fluc gene from the pGL3-attB-
CoreFluc between NcoI and XbaI sites. The plasmids expressing
shRNAs against the following regions of the HCV core-protein
sequence: 452–472 nt, 479–499 nt, and 503–523 nt, were also
constructed [16–18]. Sense and antisense strands of shRNA
oligonucleotides were synthesized, annealed and cloned into the
BamHI and HindIII sites of pSilencer-2.1-U6 neo plasmid
(Ambion, Austin, Texas ). Scrambled shRNA (control shRNA)
cloned into the same vector was used as a negative control.
Cell cultures, DNA transfections, and luciferase assays
Huh7 cells were cultured in DMEM (Gibco, Carlsbad, CA) with
10% FBS (HyClone, South Logan,UT) at 37uC in 5% CO2/air.
Transient transfections were performed by using Lipofectamine
2000 (Invitrogen, Carlsbad, CA), starting from approximately
1610
5 cells/well in 24-well dishes with 0.6 mg of a plasmid DNA
mixture following the manufacturer’s instructions. Plasmids were
purified with the Qiagen plasmid purification kits (Hilden,
Germany). In each case, 1 ng of a plasmid that had the Renilla
luciferase gene driven by the herpes simplex virus thymidine
kinase (HSV-TK) promoter (pRL-TK, Promega) was included in
the assay to monitor transfection efficiency. After 48 h, cells were
washed with PBS and harvested in 100 ml of Passive Lysis Buffer
(PLB; Promega). Firefly and Renilla luciferase activity was measured
in a GloMax
TM 96 luminometer from 20 ml of lysate using the
Dual-Luciferase Reporter Assay System (Promega).
In vivo gene delivery and determination of luciferase
expression in the mouse liver
For the long-term study, plasmids were purified with the
Endotoxin Free Maxi Kit (Qiagen, Hilden, Germany) and
administrated to C57BL/6 mice by the hydrodynamics method
[19,20]. Three C57BL/6 mice were used in each group. Ten
micrograms of DNA mixture in 1.6 ml saline was intravenously
injected in a time range of 5to 8 s. Animals were imaged in the
Xenogen IVIS-50 optical imaging system at the indicated time
described in the article.
Figure 1. Schematic diagram of plasmid and processing of the Core-Fluc fusion protein. A.Schematic representation of the plasmids used in
the present study. B. Schematic diagram of Core-Fluc fusion protein processing. pGL3-attB-CoreFluc plasmid encoded a precursor protein which was composed of
the entire core protein (aa 1–191) and Fluc protein and was further processed into two proteins (the mature core protein (p21) and Fluc) within the signal sequence
by host SPPase [15].Thus the expression level of core protein was reflected by the activity of Fluc which could be detected by the IVIS camera in whole animals.
doi:10.1371/journal.pone.0014043.g001
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Nested PCR
Animals were sacrificed after 2weeks (control group) and 3
months (test group).The livers were removed and genomic DNA
isolated using the Wizard Genomic DNA Purification Kit
(Promega) according to the manufacturer’s instructions. To detect
site specific integration at mpsL1 (mice pseudo-site from liver ), a
nested PCR approach was followed. Mice liver genome DNA was
used as template for the first round PCR with primers mspL1rev
and attB-1. The cycling conditions were 94uC for 30 s, 55uC for
30 s and 72uC for 30 s. The products were used as templates in
the second round PCR with primers mspL1rev and attB-2 under
similar conditions to those for the first round PCR. The second-
round PCR products were cloned into pGEM-T (Promega) and





Proteins were extracted from liver tissues or transfected cells
following the manufacturer’s instructions. 10 mg of proteins was
loaded on a 10% SDS–polyacrylamide gel in Laemmli sample
buffer. Proteins were separated by electrophoresis and transferred
onto a Hybond-P membrane (Amersham Pharmacia Biotech,
England). The membrane was blocked overnight at 4uCi n5 %
nonfat milk and incubated with anti-HCV-core or anti-luciferase
antibody followed by secondary antibody. Immunoreactive
proteins were visualized using SuperSignalWest Pico Chemilumi-
nescent Substrate (Pierce).
Histology
For routine histological analysis, formalin-fixed paraffin-em-
bedded liver samples were cut into sections 4 mm thick, depara-
ffinized in xylene, and dehydrated through a series of decreasing
concentrations of ethanol. Sections were stained with hematoxylin
and eosin.
Serum Alanine Aminotransferase measurement
Serum alanine aminotransferase was measured in 25 ml samples
using a microtiter plate assay (Pointe Scientific, Canton, MI)
Serum IL-6 and IL-1b measurement
IL-6 and IL-1bwere measured by immunoreactivity in a double-
sandwichenzyme-linkedimmunosorbentassay(ELISA)formatusing
commercially available kits for mouse cytokines (RapidBio Lab,
California, USA)according to the manufacturer’s recommendations.
Statistics
All data were reported as mean6SD. For statistical compari-
sons, parametrical data were compared using the Student’s t-test.
Differences were considered significant at P,0.05.
Results
Firefly luciferase activity can be used to reflect HCV core
protein expression in vitro and in vivo
To find out whether these constructs could express core protein
and Fluc, pGL3-attB-Core, pGL3-attB-Fluc and pGL3-attB-Core-
Fluc weretransfectedinto Huh7 cells respectively. Forty-eight hours
after transfection, Fluc activities were measured. The Fluc activity
was significantly higher in cells transfected with pGL3-attB-Fluc
than in those transfected with pGL3-attB-CoreFluc. No Fluc
activity was measured in cells transfected with pGL3-attB-Core
(Fig. 2A).Total lysates were separated by SDS/polyacrylamide gel
electrophoresis and probed for core protein and Fluc as well as b-
actin, using specific monoclonal antibodies. As expected, core
protein and Flucwereexpressed in cells transfectedwith pGL3-attB-
Figure 2. HCV core protein and Fluc expression in Huh 7 cells. A. Fluc expression was detected by Luciferase Assay. The pGL3- attB-Core,
pGL3-attB-Fluc, pGL3-attB-Core-Fluc vectors were transfected into Huh-7 cells. After 48 h, the cells were harvested and luciferase activity measured.
The transfection efficiency was normalized with Renilla luciferase activity and the normalized luciferase activity was plotted. B. Western blot analysis
of HCV core protein and Fluc expression. Total cell lysates were prepared from Huh7 cells, and transferred to membranes, followed by incubation
with monoclonal antibodies specific for the HCV core (top), Fluc (middle) or b-actin (bottom) that serves as a control for protein loading.
doi:10.1371/journal.pone.0014043.g002
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cells transfected with pGL3-attB-Fluc. The expression level of core
protein in cells transfected with pGL3-attB-CoreFluc was equivalent
to that in cells transfected with pGL3-attB-Core (Fig. 2B).
It had been verified that pGL3-attB-CoreFluc was successfully
expressed in cells. Then we investigated whether these constructs
could express core protein and Fluc in the mouse liver.
Hydrodynamics-based DNA injection method was employed to
deliver genes into C57BL/6 mouse liver. Bioluminescence imaging
was performed to examine Fluc activity at different time point
after DNA injection. As illustrated in Figure 3A and 3B, the Fluc
activity was significantly higher in the livers of mice transfected
with pGL3-attB-Fluc, approximately two orders of magnitude
higher than that in mice transfected with pGL3-attB-CoreFluc at
24 h after DNA injection. The transgene expression was transient
in pGL3-attB-CoreFluc transfected mice, luciferase activity was
undetectable beyond day 5. But in pGL3-attB-Fluc transfected
mice, luciferase activity remained at a high level beyond day7.
Western blot analysis was carried out to detect the core protein
and Fluc in the mouse liver (Fig. 3C). The expression level of Fluc
in mice transfected with pGL3-attB-CoreFluc was lower than that
in mice transfected with pGL3-attB-Fluc. The expression level of
core protein in mice transfected with pGL3-attB-CoreFluc was
equivalent to that in mice transfected with pGL3-attB-Core. These
results were consistent with the results in cells. All the data
suggested that the expression level of core protein determined the
Core-Fluc coexpression level in vitro and in vivo.
Core-shRNA-expression vectors inhibit core protein and
Fluc expression in vitro and in vivo
To investigate whether intracellular expression of shRNA
inhibited core protein and Fluc expression in cultured cells, three
shRNAs(shRNA452, shRNA479, and shRNA523) were designed
to target the highly conserved core region of the HCV genome.
pGL3-attB-CoreFluc and each of the shRNA expression vectors
were co-transfected into Huh-7 cells. 48 h after transfection, the
cells were lysed and Fluc activities were measured. The results
revealed that the luciferase activities were reduced by about 40–
55% in the cells co-transfected with shRNA452, shRNA479, and
shRNA523 (Fig. 4A). The inhibitory effects of these three shRNAs
Figure 3. HCV core protein and Fluc expression in the liver of C57BL/6 mice. A. Bioluminescent Imaging analysis of the Fluc activity. C57BL/
6 mice were injected with 10 mg pGL3-attB-Core, pGL3-attB-Fluc, pGL3-attB-CoreFluc respectively and monitored by bioluminescent imaging. Fluc
activity was measured 24 hours post-injection. B. Evaluation of Fluc activity in vivo over the course of the experiment.Values represent means6S.D.
(n=5). C. Western blot analysis of the HCV core protein and Fluc. Mice were transfected and sacrified at 24 hr. Fluc and core protein detection was
performed as described above.
doi:10.1371/journal.pone.0014043.g003
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Fluc activity by pU6-mediated shRNA expression vector. shRNA-Scramble vector, shRNA–Fluc vector, shRNA-452 vector, shRNA-479 vector, shRNA-523 vector
or pU6-vector (2 mg) were co-transfected with 0.5 mgp G L 3 - attB-CoreFluc vector and pRL-TK into Huh-7 cells. Luciferase reporter assay was performed 48 h
post-transfection. The transfection efficiency was normalized with Renilla luciferase activity and the normalized luciferase activity was plotted taking the
control (pU6-vector) as 100%. The presence of statistical difference has been indicated as follows: * = p,0.05; ** = p,0.01. B.Western blot analysis to
establish the effects of various shRNA expression vectors on the levels of HCV core protein. Total cell lysates wereelectrophoresed on 12% SDS polyacrylamide
gels,and transferred to membranes, followed by incubation with polyclonalantibodies for thecore protein.Andb-actin serves asa controlfor protein loading.
doi:10.1371/journal.pone.0014043.g004
Figure 5. Efficient suppression of the HCV core protein expression by pU6- shRNA vector in the mouse liver. pU6-Vector, shRNA-
Scramble vector, shRNA–Fluc vector, shRNA-452 vector or shRNA-523 vector (10 mg) were co-transfected with 10 mg pGL3-attB-CoreFluc vector into the mouse
liver. Real-time invivoimagingof FLucactivityinmice 8, 24,36and 48 hrsafter hydrodynamic injection. The presenceofstatistical difference hasbeenindicated as
follows: * = p,0.05; ** =p,0.01. The area used for calculation of light-intensities has been boxed. All the experiments shown have been repeated at least thrice.
doi:10.1371/journal.pone.0014043.g005
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Bioluminescence imaging Fluc activity in mice. Two groups of mice received a large-volume tail vein injection of 10 mg of pGL3-attB-CoreFluc with
10 mg pCS(squares) or with 10 mg pCMV-Int(diamonds). FLuc activity was monitored by bioluminescence imaging in mice throughout the
experiment. C. Western blot analysis of HCV core protein expression. Proteins were extracted from liver tissues and transferred to membranes,
followed by incubation with monoclonal antibodies specific for the HCV core (top) and b-actin (bottom) that serves as a control for protein loading.
doi:10.1371/journal.pone.0014043.g006
Figure 7. Detection of integrase-mediated site-specific recombination at the DNA level. A. Nested PCR was performed, using primers that
detect the junction between the attB site of pGL3-attB-CoreFluc and mpsL1, a preferred pseudo attP site in the mouse genome. B. The sequences
depicted the crossover region between the mouse pseudo attP site and the attB site. Shot lines represent bases missing in the novel joint. The 25 bp
nearest the crossover of each genomic P arm was compared to wild-type attP [13].
doi:10.1371/journal.pone.0014043.g007
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shRNA) had no inhibitory effect. The inhibitory effect of shRNAs
was confirmed by western blotting to detect HCV core protein
(Fig. 4B). The result showed that core protein expression was
reduced in cells co-transfected with Fluc-shRNA, shRNA-452,
shRNA-479, or shRNA-523, but not in cells co-transfected with
scramble-shRNA. The degradation of HCV core protein was
consistent with the reduction of Fluc activity.
We proceeded to investigate whether two of these shRNAs
employed in cell culture could similarly mediate a gene-silencing
effect in adult mice by transient transfection, using real-time
bioluminescence imaging. Four groups of mice were injected via
the tail vein with 10 mg of pGL3-attB-CoreFluc and 10 mgo f
shRNA-Scramble, shRNA-452, shRNA-523 or shRNA-Fluc ex-
pression vectors respectively. Bioluminescence imaging was
performed to examine luciferase expression in the liver at the
indicated time after DNA injection. As illustrated in Figure 5, the
effect of shRNA-Fluc and shRNA-523 was detectable as early as
24 h after transfection and became even more pronounced at later
time points. By contrast, the effect of shRNA-452 and shRNA-
Scramble was not detected until 48 h post-transduction.
WC31 integrase mediates elevated transgene expression
in the mouse liver
Recent studies have demonstrated the successful use of WC31
integrase, which can catalyze the integration of plasmids into the
mammalian genome at so-called ‘‘pseudo-attP’’ sites to achieve
long-term gene expression [21–24]if those plasmids contain the
attB recognition sequence. To determine the effect of WC31
integrase on the expression of the transgene, 10 mg of the pGL3-
attB-CoreFluc was injected with either 10 mg of carrier plasmid
pCS (control group) or the integrase expression vector pCMV-Int
(test group) into the tail vein of mice. The luciferase activity was
measured at different time points using the bioluminescence
method. There was a high level of luciferase expression in the
livers of all the mice 24 h after injection. When pCMV-Int was
included, transgene expression decreased ,30-fold within two
weeks and lasted until day 420 (Fig. 6A and 6B), indicating that the
integrase substantially increased and stabilized transgene expres-
sion. Mice from control group and test group were sacrificed 30
days post injection, and livers were removed from these mice.
Total protein was isolated and western blot was done to analysis
the HCV core protein expression (Fig. 6C). Genomic DNA was
isolated, and genomic integration was confirmed by nested PCR
(Fig. 7A). The resultant bands were sequenced and aligned with
the genomic sites (Fig. 7B). The switch from attB to genomic
sequence near the TTG core and the detectable sequence identity
between the genomic sequence and attP confirmed FC31-
mediated integration at genomic pseudo-attP sites. These results
further demonstrated that plasmid integration was associated with
higher sustained levels of transgene expression.
Core-shRNA-expression vectors inhibit HCV core gene
and Fluc gene expression in the stable mouse model
As seen above, shRNA523 produced a higher inhibitory effect
on the target gene, which was why shRNA523 was used for further
studies in the stable mouse model.
Three months after transfecion of pGL3-attB-CoreFluc and
pCMV-Int, the mice were imaged with BLI system and divided
into two groups. The mice were injected via the tail vein with
either 10 mg/mouse of shRNA-Scramble expression vectors or
shRNA523 expression vectors. We found that shRNA523 reduced
luciferase levels by up to 76.4626.0% (P=0.00003) (n=5, mean
6SD) and 91.868.0% (P=0.00001) (n=5, mean 6SD) com-
pared to before injection, at 6 hr and 12 hr after injection
respectively (Fig. 8). The inhibitory effect persisted for 1 day after a
single injection while shRNA-Scramble did not seem to have any
effect on the luciferase activity, suggesting the specificity of our
method.
Adverse effects of hydrodynamic injection shRNA-
encoding plasmids on the mouse liver
To investigate the shRNA hepatotoxicity, the mice were
injected with pSilencer-2.1-U6 plasmid, control non-targeting
shRNA expression vectors (shRNA-Scramble), or shRNA523
expression vectors. Serum levels of alanine aminotransferase
(ALT), a marker of liver function, were evaluated (Fig. 9A). ALT
levels were significantly increased (3322–3932 IU/L) 8 h after
injection, subsided to 167–214 IU/L by 48 h, then declined to the
baseline by 120 h. There were no significant difference observed
across all groups. In agreement with the ALT observations,
cytokine IL-6 levels in serum, which is essential for an optimal
acute-phase response after tissue damage, were very high
(1065.67–1237.50 pg/ml) across each group 8 h post injection,
subsiding to 26.00–46.87 pg/ml by 48 h, with no significant
difference observed for shRNA-Scramble, shRNA523 vs. vehicle
treatment(Fig. 9B). Another proinflammatory cytokine IL-1b levels
exhibited a rise (157.25–211.00 pg/ml) 8 h after injection,
Figure 8. Efficient suppression of the HCV core protein and Fluc expression by pU6- shRNA expression vector in stable mouse
model. shRNA-Scramble vector, or shRNA-523 vector (10 mg) were transfected into the stable mouse model. Real-time in vivo imaging of FLuc
expression in mice 6, 12, 24 and 48 hrs after injection. The luciferase activity was plotted taking the control (before injection) as 100%.The presenceo f
statistical difference has been indicated as follows: * = p,0.05; ** =p,0.01.
doi:10.1371/journal.pone.0014043.g008
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(Fig. 9C). There was also no statistical significance between the
groups. Examination of liver histology from both treated mice
revealed significant hydrodynamic injection-related hepatic injury
[25] (Fig. 10). At 8 h after injection liver morphology underwent
remarkable changes. Many hepatocytes were swollen and their
cytoplasm was vacuolized and stained less with eosin. Red blood
cells (RBCs) appeared as clusters between and inside damaged
hepatocytes. Cells developed signs of irreversible damage such as
apoptosis or necrosis, accompanied by minimal neutrophil
infiltration. Liver morphology 24 h after HTV injection was close
to normal. Single cell necrosis, swollen cells and inflammatory
infiltration were infrequent at 24 h, showing liver recovery at this
time point. At 48 h the liver morphology became more normal.
Taken together, these results indicated that liver damage observed
in the mice was due to hydrodynamic injection, and all the mice
could recover from hydrodynamic injection up to 2 days.
Discussion
HCV genome is an ssRNA that functions as both an mRNA
and a replication template so that destruction of HCV RNA could
eliminate not only virally directed protein synthesis, but also viral
replication. In cell culture, siRNA, as well as vector-encoded
shRNA directed against the HCV viral genome, specifically
targeting the HCV-59-NTR, core, NS3, NS4b, NS5a and NS5b
Figure 9. Hydrodynamic delivery shRNA effects on plasma ALT levels and cytokine IL-6/IL-1b levels in mice. C57BL/6 mice (n=5 per
group) were hydrodynamically transfected with 10 mg of shRNA-Scramble vector, or 10 mg shRNA–523 vector, or 10 mg empty control plasmid pU6-
Vector. A. Plasma ALT and, B. plasma IL-6 and, C. plasma IL-1b levels (means 6 s.d.) were determined at different time after transfection.
doi:10.1371/journal.pone.0014043.g009
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potentially promising approach to HCV infection, making it
necessary to establish user-friendly and accurate non-primate
systems for siRNA drug development.
We described here a novel method to screen anti-core protein
siRNA in the mouse liver. By using the reporter gene, anti-core
protein compounds can be screened by simply bioluminescence
imaging the Fluc activity in whole animals under true physiolog-
ical conditions.
In this study, three shRNAs targeting the highly conserved core
region of the HCV genome and the plasmid pGL3-attB-CoreFluc,
which encoded the fly luciferase (reporter gene) fusing to the
downstream of HCV core protein as a silencing target, were co-
transfected into Huh7 cells and the mouse liver. In cell culture, all the
three shRNAs caused significant reduction in the level of HCV core
protein while the sramble shRNA had no inhibitory effect on core
protein expression. This observation had been previously reported by
other groups. But Suzuki et al considered that shRNA452 construct
mediated more effective inhibition of HCV replication than the other
core-shRNAs (shRNA479 and shRNA523) [16,17]. In our test, the
inhibitory effects of these three shRNAs had no statistic difference. It
was also found that the loss of Fluc activity coincided with the
degradation of HCV core protein, which indicated that the Fluc
activity could reflect the expression level of core protein successfully. In
the transient mouse model, the inhibitory effect of shRNA452 and
shRNA523 was examined by real-time bioluminescence imaging. The
effect of shRNA-523 was detectable as early as 24 h after transfection
and became even more pronounced at later time points. The effect of
shRNA-452 was not detected until 48 h post-transduction.
There are some special requirements for assays used in drug
discovery that are related to the nature of the information needed
to understand drug action. Besides, advanced characterization of
compounds typically requires answers to questions such as the
relationship between duration of action and pharmacokinetics or
the maintenance of efficacy after repeated dosing. So a stable
mouse model can help to identify and evaluate specific compounds
for their potential efficacy.
Phage WC31 integrase has emerged as a potent tool for
achieving long-term gene expression in different tissues. Several
studies document that phage WC31 integrase can site-specifically
Figure 10. Effects of hydrodynamic injection shRNA on hepatic histology in mice. C57BL/6 mice were treated as described in the legend to
Fig. 9. Liver sections were stained with hemotoxylin/eosin. Livers were examined histologically from normal, uninjected animals(A) or from animals
sacrificed 8 h (B-D), 24 h (E–G), and 48 h (H–J) after hydrodynamic injection. Magnification, x 40.
doi:10.1371/journal.pone.0014043.g010
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positions in the genome of mouse liver cells [21,30,31]. Using
WC31 integrase, long-term expression of Core-Fluc was achieved.
However, final expression values attained were substantially lower
than the initial values at day 1 post-transfection. This is consistent
with the findings of other groups and represents a transition from
initial high levels of expression arising from unintegrated
(episomal) pDNA to steady-state expression levels resulting from
integrated pDNA[21,24,32]. In this stable mouse model, the
inhibitory effect of shRNA523 was examined, and significant
reduction in Fluc activity was observed. The inhibitory effect
persisted for 1 day after a single injection.
Short hairpin RNAs (shRNAs) have emerged as a novel
therapeutic modality, but there is increasing concern over
nonspecific effects in vivo [33,34]. Here, physiological effects of
hydrodynamic injection of shRNA were detected in mice.
Histological examination of livers at varying times post injection
revealed initial hepatic injury at 8 h after injection that appeared
to be fully resolved by 48 h.In agreement with the histology
observations, serum ALT levels were significantly increased 8 h
after injection, then declined rapidly within the next 48 hours, a
finding that had been previously reported by other groups[19,35].
Consistent with the ALT and histology observations, cytokine IL-6
and IL-1b levels, exhibited a dramatic rise 8 h after injection,
followed by a return to the baseline levels during the next
48 hours. No significant difference was seen across mice
transfected with shRNA523 expression vectors, non-targeting
shRNA expression vectors or pSilencer-2.1-U6 plasmid. Altogeth-
er, our data suggest that liver damage observed in the mice is
hydrodynamic injection method-related effects and transient
shRNA synthesis has no detectable hepatoxicity. Given these
findings, it may be important to consider background liver damage
in the interpretation of gene knockdown via hydrodynamic
injection shRNA. But proper experimental control can allow
dissection of delivery-related side effects-mediated vs. gene
knockdown- mediated changes.
In conclusion, a simple and quantitative method of real-time
monitoring of HCV core protein inhibitors in mice has been
successfully developed. Moreover, the method clearly demon-
strates that shRNA targeting HCV core protein can effectively
downregulate core gene and reporter gene expression in the liver
of mice. This luminescence-based method allows continuous
monitoring of the kinetics of HCV core protein inhibitors in live
animals. This novel and simple method can be used for screening
anti-HCV compounds.
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